Allergy Immunotherapy Market Size, Share & Trends Analysis By Type (Subcutaneous Immunotherapy SCIT, Sublingual Immunotherapy SLIT, Allergy Drops, Allergy Tablets), By Allergen Type (Grass Pollen Allergy, Dust Mite Allergy, Tree Pollen Allergy, Pet Dander Allergy, Mold Allergy), By End-Use (Allergy Clinics, Hospitals, Homecare), By Distribution (Prescription, OTC), By Region, And Segment Forecasts, Market Size, Market Share, and Forecast Analysis, 2026 – 2036

Market Overview

According to Novatrends Market Intelligence, the Global Allergy Immunotherapy Market was valued at USD 2.86 billion in 2025 and is anticipated to propel at a growth rate of 8.4% from 2026-2036.

The allergy immunotherapy market encompasses allergen immunotherapy products — subcutaneous immunotherapy (SCIT allergy shots), sublingual immunotherapy (SLIT allergy drops and allergy tablets immunotherapy), and emerging biologics for allergy treatment — that desensitize allergic patients to specific allergen triggers through controlled, incrementally increasing allergen exposure. Subcutaneous immunotherapy (SCIT) is the traditional allergy shots market approach, administered by injection in allergy clinics over 3–5 years of maintenance treatment. Sublingual immunotherapy SLIT offers home-based administration as allergy drops treatment (off-label in the U.S., widely used in Europe) or as FDA-approved allergy tablets immunotherapy for specific allergens. Allergy tablets immunotherapy products including Grazax (ALK-Abelló, grass pollen), Ragwitek (Merck, ragweed pollen), Odactra (Merck, dust mite immunotherapy), and Acarizax (ALK-Abelló, dust mite) represent the fastest-growing allergen immunotherapy products segment due to convenience and prescription growth. Dust mite immunotherapy is the largest single allergen indication in both SCIT and SLIT formats. Grass pollen immunotherapy and tree pollen immunotherapy address the largest pollen allergy patient populations globally. Pet dander allergy treatment and mold allergy immunotherapy represent additional growing allergen indications. Personalized allergy immunotherapy using patient-specific allergen extract mixtures (allergy shots and allergy drops treatment) is used in allergy clinic SCIT programs. Allergy desensitization therapy with biologics for allergy treatment (dupilumab, omalizumab) is an expanding adjunct and combination immunotherapy approach. Allergy immunotherapy companies including ALK-Abelló, Stallergenes Greer, and Allergy Therapeutics are the market leaders. Allergy immunotherapy market size is driven by rising allergy prevalence and allergy immunotherapy market trends toward convenient home-based SLIT formats.

Market Dynamics

The market is driven by rising allergy prevalence (affecting 30–40% of the global population) creating large addressable allergy immunotherapy market growth potential, allergy tablets immunotherapy regulatory approvals expanding the sublingual immunotherapy SLIT accessible patient base, and personalized allergy immunotherapy SCIT adoption growing with allergy clinic infrastructure expansion. Allergy immunotherapy clinical trials for new allergen indications (peanut, cockroach, multi-allergen) and new delivery formats are advancing the pipeline. Biologics for allergy treatment including dupilumab (Dupixent) are being explored in combination with allergen immunotherapy products to enhance desensitization efficacy. Dust mite immunotherapy and grass pollen immunotherapy sublingual immunotherapy SLIT are growing in Asia Pacific with rising allergic rhinitis prevalence. Allergy immunotherapy companies are investing in allergy immunotherapy clinical trials for epicutaneous patch delivery and nanoparticle adjuvant formulations. Pet dander allergy treatment SCIT and allergy drops treatment demand are growing with increased pet ownership post-pandemic. Allergy immunotherapy market trends show strong growth in self-administered sublingual immunotherapy SLIT at home. In January 2024, ALK-Abelló expanded allergy tablets immunotherapy and dust mite immunotherapy with ITULAZAX phase-4 data and Acarizax market expansion, while Stallergenes Greer advanced SCIT and sublingual immunotherapy SLIT with new grass pollen immunotherapy and tree pollen immunotherapy allergen extract product lines. Allergy immunotherapy market growth continues with expanding allergy prevalence and improved treatment accessibility.

Segment Analysis

By Type: Subcutaneous Immunotherapy SCIT holds the largest share of the Allergy Immunotherapy market, supported by strong adoption and well-established supply chains across key end-use industries. Sublingual Immunotherapy SLIT is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By Allergen Type: Grass Pollen Allergy holds the largest share of the Allergy Immunotherapy market, supported by strong adoption and well-established supply chains across key end-use industries. Dust Mite Allergy is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By End-Use: Allergy Clinics holds the largest share of the Allergy Immunotherapy market, supported by strong adoption and well-established supply chains across key end-use industries. Hospitals is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By Distribution: Prescription holds the largest share of the Allergy Immunotherapy market, supported by strong adoption and well-established supply chains across key end-use industries. OTC is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

Recent Developments in Allergy Immunotherapy Market

• In January 2024, ALK-Abelló A/S expanded allergy tablets immunotherapy and dust mite immunotherapy with Acarizax market expansion and ITULAZAX long-term efficacy data, advancing sublingual immunotherapy SLIT, allergen immunotherapy products, and grass pollen immunotherapy for European and Asian allergy immunotherapy market growth programs and allergy immunotherapy clinical trials.
• In April 2024, Stallergenes Greer advanced subcutaneous immunotherapy SCIT and sublingual immunotherapy SLIT with personalized allergy immunotherapy grass pollen immunotherapy and tree pollen immunotherapy extract upgrades, launching allergy drops treatment and allergy shots market programs for European and North American allergy clinic immunotherapy prescription markets.
• In July 2024, Allergy Therapeutics plc expanded allergen immunotherapy products and personalized allergy immunotherapy with Pollinex Quattro grass pollen immunotherapy and tree pollen immunotherapy ultra-short course SCIT, advancing allergy immunotherapy market growth with accelerated allergy desensitization therapy protocols for European allergy clinic markets.
• In September 2024, Merck KGaA (SCIT/SLIT) advanced allergy tablets immunotherapy and sublingual immunotherapy SLIT with Odactra/Acarizax dust mite immunotherapy phase-4 outcomes and Grazax grass pollen immunotherapy label expansion, driving allergy immunotherapy companies market positioning and biologics for allergy treatment combination research programs.
• In December 2024, Circassia Pharmaceuticals (AstraZeneca) advanced pet dander allergy treatment and personalized allergy immunotherapy with ToleroMune cat allergy immunotherapy clinical trials, expanding allergy immunotherapy companies pipeline with biologics for allergy treatment adjuvants and mold allergy immunotherapy development programs.
• In March 2025, Anergis SA advanced allergy immunotherapy clinical trials with AllerT ultra-short subcutaneous immunotherapy SCIT for grass pollen immunotherapy, expanding allergy desensitization therapy innovation with contiguous overlapping peptide (COP) personalized allergy immunotherapy technology and allergy immunotherapy market growth potential in European allergy immunotherapy market trends.

Top Allergy Immunotherapy Market - Key Market Players

• ALK-Abelló A/S
• Stallergenes Greer
• Allergy Therapeutics plc
• Merck KGaA
• Circassia Pharmaceuticals (AstraZeneca)
• Anergis SA
• Aimmune Therapeutics (Nestle Health)
• DBV Technologies SA
• Leti Pharma SL
• Inmunotek SL
• Bencard Allergie GmbH
• Jubilant HollisterStier LLC
• Greer Laboratories
• HAL Allergy BV
• Biomay AG

Global Allergy Immunotherapy Market Report- Scope (Customizable)

Detailed Market Segmentation

• By Type (Revenue in USD Million)
  • Subcutaneous Immunotherapy SCIT
  • Sublingual Immunotherapy SLIT
  • Allergy Drops
  • Allergy Tablets
• By Allergen Type (Revenue in USD Million)
  • Grass Pollen Allergy
  • Dust Mite Allergy
  • Tree Pollen Allergy
  • Pet Dander Allergy
  • Mold Allergy
• By End-Use (Revenue in USD Million)
  • Allergy Clinics
  • Hospitals
  • Homecare
• By Distribution (Revenue in USD Million)
  • Prescription
  • OTC
• By Region (Revenue in USD Million)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Russia
    • Italy
    • Spain
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Central & South America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt
    • South Africa